Results 61 to 70 of about 21,372 (208)

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia

Cell Death and Disease
Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy is often compromised by the development of drug resistance.
Chang-qing Jiao, Chen Hu, Meng-hua Sun, Yan Li, Chao Wu, Fei Xu, Lei Zhang, Fu-rong Huang, Jun-jie Zhou, Ji-fei Dai, Min Ruan, Wen-chao Wang, Qing-song Liu, Jian Ge   +13 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Venetoclax-associated interstitial pneumonitis

Venetoclax is a selective inhibitor of the antiapoptotic protein B-cell lymphoma 2 (BCL-2). It is approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) in combination with ...
Atif Saleem Siddiqui
core   +1 more source

Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia [PDF]

, 2018
BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells.
Marco Montillo, Boyer, M., Kater, A. P., Seymour, John F., Arnon P. Kater, De la Serna, J, D’Rozario, J, Li, Y., Robak, Tadeusz, Humerickhouse, R., Jaeger, U, Cartron, Guillaume, Owen, C., Cartron, G., Kipps, T. J., Owen, Carolyn, Thomas J. Kipps, Assouline, S., Seymour, JF, Eichhorst, B., Owen, C, Assouline, Sarit, Humphrey, K, Punnoose, EA, Cartron, G, Kipps, TJ, Humerickhouse, Rod, Sarit Assouline, Guillaume Cartron, Ulrich Jaeger, John F. Seymour, Mobasher, M., Seymour, J. F., Montillo, M., Kater, Arnon P., Jaeger, U., Robak, T, Eichhorst, B, Boyer, Michelle, Humphrey, K., Javier De la Serna, Jaeger, Ulrich, D'Rozario, James, de la Serna, J., Hillmen, Peter, Li, Yan, Michelle Boyer, Gerecitano, J, Montillo, M, Barbara Eichhorst, Carolyn Owen, Rod Humerickhouse, Montillo, Marco, Yan Li, Kathryn Humphrey, D'Rozario, J., Gerecitano, John, Tadeusz Robak, Kater, AP, Mobasher, Mehrdad, Punnoose, E. A., Gerecitano, J., Assouline, S, Robak, T., Humerickhouse, R, Punnoose, Elizabeth A., Serna, Javier,, Hillmen, P., Peter Hillmen, James D’Rozario, Elizabeth A. Punnoose, Li, Y, Mobasher, M, Kipps, Thomas J., Humphrey, Kathryn, Eichhorst, Barbara, Hillmen, P, Mehrdad Mobasher, John Gerecitano, Boyer, M   +79 more
core   +1 more source

Time to onset of venetoclax-related AEs.

, 2022
Time to onset of venetoclax-related AEs.
Yamin Shu (4728618), Yang Yang (45629), Yanchao Yin (14232485), Juan Li (146180), Feie Li (14232488), Guosong Chen (1397413)   +5 more
core   +1 more source

Outpatient initiation of venetoclax in patients with acute myeloid leukemia

, 2022
INTRODUCTION: Venetoclax is a treatment option in patients with acute myeloid leukemia (AML) in both the front-line and relapsed/refractory settings. Initiation of therapy has been previously restricted to the inpatient setting at some institutions due ...
Foster, Matthew, Wang, Christopher, Patel, Bianka, Muluneh, Benyam, Patel, Anand, Buhlinger, Kaitlyn, Palmer, Shannon, Zeidner, Joshua   +7 more
core   +1 more source

Interindividual variability in CYP3A‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Clinical and Translational Science
Venetoclax is a first‐in‐class orally administered B‐cell lymphoma‐2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3,
Jonghwa Lee, Jessica L. Beers, Isabel Cheng, Vivian Truong, Zachary Brown, Benyam Muluneh, Catherine C. Coombs, Klarissa D. Jackson   +7 more
doaj   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Development of venetoclax for therapy of lymphoid malignancies

, 2017
Huayuan Zhu,1,2 Alexandru Almasan1 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; 2Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing,
Zhu H, Almasan A
core